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Introduction
The introduction of highly active antiretroviral therapies (HAART) 
including protease inhibitors and non-nucleoside reverse transcriptase 
inhibitors dramatically decreased the mortality of AIDS since 1996 [1,2] 
but also made apparent possibilities and limitations of antiretroviral 
therapy.  Sustained  viral  suppression  depends  on  a  number  of 
factors, which have to be controlled by the patient and physician. (i) 
HIV therapy only is effective over a longer period of time, if taken 
continuously  and  adherently  by  the  patient.  (ii)  The  management 
of  numerous  side  effects,  such  as  haematological  abnormalities, 
dyslipidemia,  polyneuropathy,  mitochondrial  toxicities,  insulin 
resistance, organ toxicities and lipodystrophy, to mention only a few, 
is a challenge for physicians. (iii) Viral resistance and cross resistance 
within all classes of antiretroviral drugs are complicating the situation 
and lead to therapy failures increasing with the duration of HAART.
Treatment  response  rates  range  from  70-90%  in  therapy  naïve 
patients but decline to approximately 50% in patients who received 
several HAART during treatment history [3]. 
HIV protease inhibitors and non nucleoside reverse transcriptase 
inhibitors (NNRTI) plasma concentrations display a high inter- [4-
8] and intraindividual variability [9-11]. The therapeutic window is 
comparably narrow as drug concentrations expected to be toxic are 
only 3-5 fold higher than antivirally effective concentrations in vivo. 
This  is  a  therapeutic  setting  that  suggests  establishing  personalized 
dosing regimens to tailor the ARV plasma concen  trations with the 
intention to maximize therapy success and minimize side effects in the 
individual. In fact, therapeutic drug monitoring of antiretroviral drugs 
has been suggested by various authors and guidelines [12-23].
However, data and advice for clinicians on the individualization 
of HAART is rather rare. And personalizing therapy by modifying 
the dosing regimen bears the danger of losing therapeutic efficacy or 
increasing  side  effects.  It  is  good  clinical  pharmacological  practice 
to  base  personalized  dosing  on  quantitative  information  about  the 
relationship  between  patient’s  individual  variables,  viral  resistance 
patterns,  co-administered  drugs  and  plasma  concentrations,  and 
between plasma concentrations and therapeutic effects. 
This  topical  review  identifies  pharmacokinetic  and 
pharmacodynamic  models  of  antiretroviral  therapy  appraising  the 
potential application to HIV therapy.
Target plasma concentrations in HAART naive patients
Once  an  effect  versus  plasma  concentration  relationship  has 
been established, methods such as therapeutic drug monitoring up 
to  population  pharmacokinetics  [24]  are  available  to  individually 
adapt the dosing regimen. Target plasma concentrations as minimum 
effective  concentrations  (MEC)  of  protease  inhibitors  and  NNRTI 
have  been  defined  and  extrapolated  from  studies  in  therapy-naïve 
patients  [25,26]  or  in  vitro  data.  Three  interventional  studies  used 
a  similar  minimum  indinavir  concentration  threshold,  ranging 
from  0.10-0.15  μg/mL  (ATHENA  and  GENOPHAR  studies)  [27-
29]. The GENOPHAR study also defined in vivo Cmin-thresholds for 
ritonavir (>2.1 μg/mL), amprenavir (>1.0 μg/mL), lopinavir (>3.0 μg/
mL) and saquinavir (250 ng/mL) [29]. Four studies set the nelfinavir 
Cmin threshold between 0.52 and 1.0 μg/mL. All studies based their 
threshold recommendations on the protein-binding adjusted IC50 or 
IC95-values. Two studies defined an efavirenz Cmin-threshold of >1.0 μg/
mL and an optimum AUC of >60.0 μg×h/mL [30,31] on basis of the 
data, obtained from the registrational studies with efavirenz [32]. One 
study found a better virologic response to nevirapine therapy at plasma 
Cmin concentrations of >4.3 μg/mL [33].
A  considerable  number  of  observational  studies  showed  a 
correlation between drug plasma concentrations of PIs and virological 
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suppression prospectively followed up in phase II studies (saquinavir, 
indinavir,  amprenavir,  darunavir).  The  same  has  been  shown  for 
treatment-naive  patients,  either  in  phase  III  studies  (saquinavir, 
nelfinavir, ritonavir) or commencing HAART in clinics (saquinavir, 
nelfinavir, indinavir, ritonavir) [34,35]. 
In  general  the  association  between  drug  concentrations  and 
virological  response  varies  and  is  less  clear  in  therapy  experienced 
patients.
Target  plasma  concentrations  in  treatment  experienced 
patients
Several studies addressed the question whether a correlation of 
virological  and  clinical  data  to  pharmacokinetics  predicts  therapy 
response on protease inhibitors in extensively pretreated patients. In 
order to sufficiently and sustained suppress a resistant virus, it can be 
necessary  to  achieve  high  plasma  concentrations  of  antiretrovirals, 
governed by the viral phenotype. As phenotypic testing is not part 
of diagnostic routine, these studies emphasized on the combination 
of  virological  genotype  with  pharmacokinetic  parameters.  Thus, 
the  genotypic  inhibitory  quotient  (GIQ)  is  the  ratio  of  the  trough 
concentration  of  antiretroviral  agents  to  the  number  of  resistance 
mutations  detected  in  the  viral  genotype.  This  concept  has  been 
confirmed for lopinavir, atazanavir, amprenavir and saquinavir and 
other protease inhibitors in a number of clinical trials with therapy-
experienced patients [36-42]. 
Approach to Clinical Dose-response Models
A. Common two step approaches were used in most evaluations 
of  HAART  pharmacokinetics.  Data  assessed  in  clinical  settings 
were either analysed in non-compartmental models or fitted to one-
compartment analyses. Thus, mean drug concentrations to be expected 
in diverse populations were evaluated. 
B. Population pharmacokinetic approaches tried to evaluate and 
quantify the factors of influence on HAART pharmacokinetics applied 
to different populations [43]. Population pharmacokinetics has been 
used to explore and define relevant cofactors for variation in drug 
exposure and response in patient populations. Up to date, population 
pharmacokinetic analyses of more than twenty available antiretrovirals 
have been published [44-60].
C. Pharmacokinetic/pharmacodynamic models have been used to 
characterize the (i) relationship between drug exposure and virological 
and  immunological  response,  and  to  predict  clinical  outcome. 
Modelling and simulation approaches have evaluated (ii) antiretroviral 
agent  outcomes  incorporating  problematic  design  and  analysis 
factors,  i.e.  sparse  plasma  sampling,  data  imbalance  and  censored 
data.  Additional  population  modelling  approaches  include  (iii)  the 
assessment  of  dosing  compliance,  understanding  and  quantifying 
drug-drug  interactions  in  order  to  select  dosing  regimens  and  the 
screening of new drug candidates. 
Although these models offer an opportunity for individualizing and 
optimizing patient therapy, particularly when adjusted for adherence/
compliance, the impact of population pharmacokinetics on clinical 
antiretroviral therapy is rather restricted, except its contribution to the 
current regulatory environment, specifically in the area of accelerated 
approval of new antiretroviral agents.
Population pharmacokinetic studies
Population  pharmacokinetic  models  for  nelfinavir  detected  a 
number of variables influencing significantly drug concentrations in 
patients. Very young age, pregnancy and comedication were the three 
main reasons for a very high variability of values. Neither body weight, 
age, sex, race, dose level, baseline viral load, metabolite-to-parent drug 
plasma concentration ratio, history of liver disease, nor elevated results 
of liver function tests appeared to be significant covariates for nelfinavir 
clearance [48-50]. 
The individual indinavir clearance in patients was only decreased 
by  the  concomitant  intake  of  the  pharmacoenhancer  ritonavir,  but 
not other demographic or clinical covariates [47]. The same counts 
for  amprenavir,  atazanavir  and  lopinavir  [44,45,56].  Efavirenz  and 
nevirapine plasma concentrations of the two currently used NNRTI 
in  HIV  therapy  were  found  to  be  correlated  with  impaired  liver 
function and ethnicity [54,55,61]. Higher NNRTI levels in women or 
Asian patients and a higher efavirenz clearance in white Americans 
compared to African Americans or non-white Hispanics were detected: 
cytochrome  genetic  subtypes  influence  the  pharmacokinetics  of 
NNRTI significantly and were also found to be correlated with therapy 
outcome [62].
As  physiological  changes  associated  with  pregnancy  have  a 
large  impact  on  the  pharmacokinetics  of  many  drugs,  a  nelfinavir 
population study analysed the large inter-subject variability 133 HIV-
1 infected pregnant and nonpregnant women [48]. The population 
pharmacokinetic model described the concentration time course of 
nelfinavir and its metabolite M8, whereas individual characteristics, 
such as age, body weight, and weeks of gestation or delivery, were 
investigated. During late pregnancy, significant increases in nelfinavir 
(44.4 liters/h) and M8 (5 h(-1)) elimination but unchanged nelfinavir 
transformation clearance to M8 were observed and nelfinavir clearance 
showed a twofold increase on the day of delivery, suggesting a decrease 
in bioavailability on this day. The Bayesian individual pharmacokinetic 
estimates suggested that the dosage should not be changed in pregnant 
women but may be doubled on the day of delivery.
Pharmacokinetic/pharmacodynamic modelling
Surrogate  parameters  such  as  the  HI  viral  load  and  the  CD4 
cell count provide direct markers for success or failure of HAART. 
Thus,  diverse  models  correlated  dose  and  plasma  concentration  of 
antiretrovirals to the immunological and virological therapy outcome.
Viral dynamics: A number of nonlinear mixed effects mechanism-
based  models  were  established  to  estimate  individual  unknown 
dynamic parameters characterizing viral dynamics during HAART. 
Wu et al. [63] incorporated drug concentrations of the protease 
inhibitors indinavir/ritonavir, adherence and drug susceptibility into 
a function of treatment efficacy, defined as an inhibition rate of viral 
replication. Forty-four patients who failed their first protease inhibitor 
containing  treatment  were  randomized  to  two  different  indinavir/
ritonavir  regimens,  taking  either  800/200  mg  BID  or  400/100  mg 
BID. However, viral parameters identified conferring to the efficacy of 
HAART was the subject-specific pharmacokinetics of antiretrovirals 
and  phenotypic  drug  susceptibility  to  HAART.  It  was  shown  that 
standard regression/correlation analyses could not identify significant 
relationships  between  antiviral  response  and  drug  exposure  or 
susceptibility. Finally, Bayesian estimation approaches were able to fit 
viral load data for the individual subjects, such as fluctuation and viral 
rebound, to the model and identify the complicated pharmacodynamic 
relationships  with  confounding  factors.  As  an  example  for  this 
approach the final model of Wu et al. [63] is shown in equation 1.Citation: Hentig NV (2013) Personalizing HIV Therapy, Mission Impossible? J Antivir Antiretrovir 5: 012-020. doi:10.4172/jaa.1000058
Volume 5(1): 012-020 (2013) - 014 
J Antivir Antiretrovir
ISSN: 1948-5964 JAA, an open access journal
Equation 1: Emax model for the drug efficacy of a single agent.
50
( )
( )
( ) ( )
C t
t
IC t C t
γ =
Φ =
                                                                           (1)
γ(t) ranges from 0 to 1 and indicates the drug efficacy; C (t)=drug 
plasma concentration; Φ=conversion factor between IC50(t) in vitro 
and IC50(t) in vivo.
However,  the  model  employed  by  Wu  et  al.  (2005)  identified 
similar  effects  of  the  four  pharmacokinetic  parameters  Ctrough, 
C12hour, Cmax and AUC on virological response, thus providing useful 
information for future analyses, as Ctrough is the easiest to obtain in 
clinical settings. Adherence, measured by pill count did not improve the 
pharmacodynamic model and the drug susceptibility provided instead 
more additional information to the adherence as the susceptibility of 
the virus to protease inhibitors is expected to depend on adherence over 
a longer period of time, which can only be estimated roughly by pill 
counts. Most complicated seems to be the application of mathematical 
models for HIV dynamics to clinical data. However these have resulted 
in important findings on the pathogenesis of HIV infection. A HIV 
viral dynamic model incorporating the effect of HAART, consisting of 
NRTI and PI, is a system of non-linear differential equations, as given 
in equation 2 [64].
Equation 2: HIV viral dynamic model incorporating the effect of 
an antiretroviral regimen.
max 1 (1 / ) [1 ( )] T
d
T pT T T d T t kTV
dt
λ γ = + − − − −
1 [1 ( )] p p
d
T t kTV T
dt
γ δ = − −
1 0 1 (1 )[1 ( )] P
d
V t N T cV
dt
η η δ = − − −
0 1 {1 (1 )[1 ( )] NI P N
d
V t N T cV
dt
η η δ = − − − −                                            (2)
T=target  uninfected  cells;  Tp=infected  cells;  V1=infectious 
virions;  VNI=non-infectious  virions;  λ=rate  of  generation  of  new 
cells,  p=proliferation  rate,  Tmax=T  cell  population  density  at  which 
proliferation shuts off; dT=rate of death of uninfected cells; δ=rate of 
death of infected cells; k=infection rate; c=clearance of free virions; 
N=number of virions produced from infected cell during its life-time; 
η0=proportion of non-infectious virions before initiation of therapy; 
γ(t)=time varying Emax model as defined in 2. 
This  model,  taken  here  as  an  example,  describes  non-linear 
functions  for  the  number  of  target  uninfected  cells,  infected  cells, 
infectious virions and non-infectious virions, respectively. It includes 
the (i) rate at which new T cells are generated within the body, (ii) 
the T cell population density at which proliferation shuts off, (iii) the 
infection rate and (iv) the rates of death of infected or uninfected T 
cells, (vi) the number of virions produced from infected cells during 
their life-time, (vii) the clearance rates for free virions and the (viii) 
proportion  of  non-infectious  virus  in  the  total  virus  pool  before 
initiation of therapy. Huang et al. [65] then included time-dependent 
parameters and drug Emax models of PI and NRTI, respectively as given 
in equation 3.
Equation 3: Best model and sum of squared deviations from a viral 
dynamic model fitting for individual subjects using the Kruskal-Wallis 
test  and  the  sign  test,  for  a  protease  inhibitor  (indinavir/ritonavir) 
containing antiretroviral therapy:
A (t) = 1 and IDV/RTV Ctrough and IC50 (t), 
1 2 2
1 50
1 1 2 2
50 50
( ) [ ( ) / ( )]/
[ / ( ) / ( )]
trough trough
trough trough
Y t C A t C IC t
C IC t C IC t
= +
Φ + +
                                                  (3)
A represents the pill count at time (t), IDV/RTV=antiretroviral 
agents  indinavir/ritonavir,  Ctrough=trough  plasma  concentration; 
IC50=Concentration  at  which  50%  of  viral  replication  is  inhibited; 
Φ=conversion factor between IC50(t) in vitro and IC50(t) in vivo.
Finally, a method for the determination of the inhibitory potential 
oh anti-HIV drugs should be discussed, although it has not found 
broad intention yet. Shen et al. [66] presented a work including the 
instantaneous inhibitory potential, IIP, of antiretrovirals into clinical 
consideration. The IIP includes the initial slope of the log-reduction 
of viral load into a median effect model, based originally on the IC50 
of a drug in vitro and the measured plasma concentrations in vivo. 
The initial slope values have a marked effect on antiviral activity, thus 
complementing the information given by IC50 and IQ. The authors 
state, “that a drug with m=3 (m is the slope-parameter) in equation 4 
produces a 10.000-fold greater inhibition at IQ=100 than a drug that 
would be judged equally potent based on the IC50 or IQ, but with m=1”. 
The authors conclude that conventional pharmacodynamic indices are 
insufficient to appraise the real antiviral activity of different drugs. This 
concept, however, has been used in drug development so far, but not in 
clinical considerations regarding HAART for, e.g. multiple pretreated 
patients  and  of  course,  prospective  studies  regarding  this  issue  are 
lacking [66,67].
Equation 4: Slope and instantaneous inhibitory potential:
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m
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In  equation  (A)  fa  is  the  fraction  of  binding  events  affected  or 
inhibited by a drug, fu is the fraction uninhibited, D is dose, IC50 is the 
dose causing 50% inhibition of the virus, and m is the slope parameter.
Equation  (B)  directly  calculates  the  fraction  of  virus  that  are 
inhibited or not by a drug and equation (C) linearizes the dose-response 
curves by plotting log( / ) a u f f  vs. log( ) D ; m is the slope of this line.
Immunological response: Another approach is the modeling of the 
CD4 cell count evolution under protease inhibitor containing HAART 
and the relation to the emergence of opportunistic infections presented 
by Binquet et al. [68] as shown in equation 5. Immunologic response 
to HAART also is an important parameter of clinical efficacy, but as 
the CD4 cell evolution is not directly correlated to viral load decrease 
difficult to predict in the individual patient. However, it was shown that 
a rapid increase was apparent during the first two months of therapy 
(an average of 23.5 cells/mm³/month) subsequently slowing down the 
following 10 months (6.4 cells/mm³/months). After 120 days each 50 
cell/mm³ increase in CD4 cell count was associated with an average 
60% decrease of the incidence of opportunistic infections. However, 
up  to  date,  no  direct  correlations  between  CD4  cell  evolution  and 
viral load decline could be modelled for protease inhibitor containing 
therapies. Recent publications suggest that HIV protease inhibitors Citation: Hentig NV (2013) Personalizing HIV Therapy, Mission Impossible? J Antivir Antiretrovir 5: 012-020. doi:10.4172/jaa.1000058
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block the apoptosis of CD4 cells independently from their antiviral 
efficacy [69,70]. 
Equation 5: Model for the CD4 cell evolution under HAART.
0 0 ( , ) ( )exp( [ 4( )
4(0)] [ 4( ) 4(0)] after  )
h t Z h t X CD t
CD CD t CD
β β
β τ
′ = = −
′′ + −
 
Z=vector of explanatory variables, X=vector of fixed covariates, 
included  in  Z;  CD4(t)–CD4(0)=CD4  value  estimated  by  a  linear 
mixed effects model, measured by  β′  before time τ  and by  β β ′ ′′ +  
thereafter.
Clinical  Scenarios  for  Personalized  Antiretroviral 
Therapy
Children
Drug concentrations in children are very difficult to predict due 
to their developmental changes strongly affecting the bioavailability of 
antiretroviral drugs. Data about the pharmacokinetics of HAART in 
children, especially below the age of three years, are scarce. A limited 
number of heterogeneous studies on the use of abacavir, nevirapine, 
efavirenz, lopinavir [71-73], saquinavir, nelfinavir [46,49] and indinavir 
[74] can be found and the majority shows a very high variability of 
plasma concentrations in children with the potential of suboptimal drug 
exposure. Children therefore would be a group for an individualized 
dose adjustment on basis of consecutive pharmacokinetic assessments 
during development. Current generalized dose recommendations may 
not be suitable for the individual pediatric patient [72,74].
Some  population  pharmacokinetic  approaches  tried  to  relate 
children’s  demographics,  and  changing  physiological  parameters  to 
ARV pharmacokinetics, i.e. zidovudine [75], abacavir [76], nelfinavir 
[46,49]  and  enfuvirtide  [57,59],  and  recently  lopinavir  [48].  It  was 
found that especially body weight, body surface area and drug clearance 
changing with age are most predictive for the pharmacokinetics of 
ARVs.
Pregnancy
HAART  during  pregnancy  also  needs  close  monitoring.  It  has 
been shown in several TDM studies that plasma concentrations of 
most  PI  are  substantially  reduced  especially  in  the  third  trimester 
[77]. Pathophysiological changes in absorption due to reduced gastric 
acid  secretion,  prolongued  gastric  and  intestinal  transit  time,  an 
increased volume of distribution due to an increase of body fat and 
water and alterations in hepatic and renal drug elimination affect at 
least saquinavir [78], nelfinavir [79], indinavir [79] and lopinavir, and 
most probably also other protease inhibitors. Data about nevirapine 
are contradictory and plasma concentration decreases [80] were as 
well reported as unchanged exposure, but higher variability [81,82]. 
A TDM-based dose optimization of nevirapine during late pregnancy 
has not been investigated yet, although recent publications showed 
the  emergence  of  NNRTI  resistance  mutations  after  therapy  with 
nevirapine in the third trimester [83]. 
One study with saquinavir/ritonavir 800/100 mg plus nucleosides 
BID defined a target plasma AUC of >10 μg×h/mL and increased the 
dose up to saquinavir/ritonavir 1200/100 mg BID if patients did not 
reach the target plasma concentrations after two weeks on treatment 
[78]. 
A successful use of TDM in pregnancy suggests pharmacokinetic 
assessments on time for a potential dose optimization, but current 
knowledge and clinical trials addressing this question are rather rare. 
Only one study is available, evaluating the population pharmacokinetics 
of nelfinavir, a protease inhibitor not used any more during for the 
prevention of mother-to-child transmission of HIV [48].
Ethnic differences in pk/pd of HAART
To  date  there  is  certain  knowledge  about  ethnic  differences 
influencing  the  pharmacokinetics  of  HAART,  especially  regarding 
genetic variations of the cytochrome P450 expression and a variety of host 
receptors, cytokines, chemokines, cellular and transcriptional factors. 
The variation of cytochrome expression in different ethnic groups with 
a  substantial  influence  on  plasma  concentrations  of  antiretrovirals 
has been described. 15% of the asian/oceanian population are poor 
metabolizers of nelfinavir due to a decreased expression of CYP2C19 
in comparison to only 2-4 percent of the caucasian, african, african-
american, arabian or native australian population [84]; and 3 to 4% of 
caucasians are poor metabolizers of efavirenz due to a polymorphism 
of  CYP  2B6.  Although  the  knowledge  about  ethnic  differences  in 
pharmacogenomics is growing rapidly, the impact on clinical TDM is 
rather small. Actually, there is no recommendation for a pre-emptive 
screening of pharmacogenetics in patients commencing HAART and 
only two population-pharmacokinetic studies retrospectively evaluated 
the impact of ethnic variations in the pharmacokinetics of efavirenz, 
nevirapine, nelfinavir and indinavir [50,54,55,61].
Renal/hepatic impairment
Changes in pathophysiological states can affect hepatic or renal 
function und thereby change drug disposition [85-93]. Adjusting the 
ARV dose can be necessary in case of hepatic (protease inhibitors, 
NNRTI) or renal impairment (NRTI). Progression of liver damage 
increases the risk for markedly elevated protease inhibitor or NNRTI 
concentrations and it has been described that patients with replicating 
hepatitis  B/C  viruses  with  or  without  signs  of  hepatic  impairment 
exhibit  markedly  increased  drug  concentrations,  leading  to  toxic 
reactions [88]. Thus a replicating HBV or HCV infection is an indication 
for a close monitoring of HAART, and perhaps dose adjustment or as 
a final consequence a change of therapy, if dose adjustment is unable 
to decrease or avoid certain toxicities. Simulation models may help to 
individually adjust doses according to patient’s renal or hepatic status. 
However, models for this approach are lacking. TDM should also be 
considered in patients with chronic gastrointestinal diseases where mal 
absorption may occur.
Toxicities
In relation to toxicities, high plasma concentrations of protease 
inhibitors  and  NNRTI  have  been  associated  with  renal/urological 
toxicity  (indinavir)  [74,94],  gastrointestinal  disorders  (ritonavir, 
nelfinavir,  lopinavir,  saquinavir)  [34,95],  hyperbilirubinemia 
(atazanavir)  [96-98],  hyperlipidemia  (lopinavir/ritonavir,  efavirenz) 
[99-101] and central nervous system side effects (efavirenz [30,102]). 
The controversial results on elevated lipids and lipodystrophy led to the 
conclusion that these toxicities may be due to multifactorial geneses, 
including host genetics and are time-dependant, increasing the risk 
for body fat composition changes over cumulative time on treatment 
[103]. 
One study found that a dose reduction of indinavir in a small 
number of patients reduced renal urological complications, but could 
not find a reduction in toxicity with a dose adjustment for nelfinavir. 
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efavirenz levels above the target concentration range (24%) compared 
to patients within the target concentration range (9%).
Drug-drug interactions
Drug-drug  or  drug-food  interactions  may  result  in  reduced 
efficacy  or  concentration-related  toxicity.  All  protease  inhibitors 
and NNRTI are metabolized by cytochrome P450 isoenzymes [104], 
which are apparent in the intestinal mucosa and in hepatocytes [105-
109], and therefore are subject to interactions among each other and 
with other drugs. Protease inhibitors are also substrates of a number 
of  cellular  transmembrane  efflux  proteins,  such  as  P-glycoprotein 
and multidrug resistance proteins (MRP-1 and 2) [110-114]. These 
transmembrane  transporters  can  limit  the  absorption  of  protease 
inhibitors and the permeation into sanctuary sites for HIV such as 
brain, lymphocytes, testes and macrophages. These interactions can 
affect drug concentrations in target tissues and plasma, and although 
the impact on plasma concentrations is less obvious, the variability in 
the admittance of antiretroviral drugs to certain compartments in vivo 
may have a substantial influence on therapy outcome of HAART [115]. 
Nevertheless, knowledge about the clinical implications and possible 
changes in HIV therapy as reaction to e.g. genetic deviations in one 
of the transporter genes remain restricted and there is no concept of 
personalization of HIV therapy based on results of pharmacogenetic 
research so far.
Much  more  is  known  about  drug-drug  interactions  involving 
cytochrome P450 isoenzymes. There is a clear recommendation for 
TDM if a therapy regimen contains combinations of double PI, PI + 
NNRTI or NNRTI/PI + known enzyme inducers or inhibitors. Other 
key interactions affecting plasma concentrations of protease inhibitors 
and  NNRTI  are  with  acid  reducing  agents,  such  as  proton  pump 
inhibitors,  H2-receptor  blockers  and  antacids,  furthermore  anti-TB 
therapy or anti-neoplastics.
Several  population  pharmacokinetic  studies  evaluated  the 
modulating effects of co-medications on HAART pharmacokinetics 
without adding new information to previous two-step approaches, at 
least regarding clinical dose recommendations. Reduced or enhanced 
bioavailability  due  to  induction/inhibition  of  drug  metabolism  or 
reduced bioavailability due to altered absorption is no new information 
on drugs which have previously been extensively pharmacokinetically 
evaluated.  Up  to  date,  CYP  or  drug  transporter  genetics  have  not 
expanded into pk/pd modeling of drug-drug interactions.
Controlled  Trials  Evaluating  the  Personalization  of 
HIV Therapy
Only  a  small  number  of  interventional  studies  evaluated  the 
question if the personalization of HIV therapy is superior to standard 
of care. 
Currently,  eight  controlled  clinical  trials  evaluating  the  role  of 
TDM for safety and efficacy of ART have been published.
Two  of  these  can  show  a  significant  therapeutic  advantage  for 
patients through TDM, i.e. the proportion of patients with a low viral 
load is higher after 48 weeks on therapy than in the control group. 
However these have been evaluated in trials with old PIs indinavir and 
nelfinavir, which are not used any more in modern ART [27,28].
Three  further  studies  miss  the  goal  to  show  a  significant 
advantage of TDM modulated ART [29-31], One study carried out 
with efavirenz defined a plasma concentration cut-off for an efficient 
antiviral treatment of 1 μg/mL and an AUC of 60.0-120.0 μg×h/mL. 
Concentrations below this level were seen to confer development of 
viral resistance and concentrations above 4.0 μg/mL were correlated 
to increased CNS toxicity [30]. Efavirenz doses of patients who did not 
match with these criteria or experienced adverse events were altered 
successfully. Naturally, the reported results could not show statistically 
significant differences between the groups and were not sufficiently 
powered to proof non-inferiority of the TDM-based individual dosing. 
A second substudy of efavirenz treatment in 50 children successfully 
evaluated the use of intrapatient variability as predictor for therapy 
outcome [31], but although a considerable number of these children 
showed efavirenz AUCs below 60.0 μg×h/mL, no dose alterations were 
made. 
At least Best et al. could show 2007 a better virological response 
after TDM based dose escalation of a PI [116]. A recently published 
work of Demeter and colleges could indeed not show a general clinical 
benefit  towards  a  better  virological  response  through  TDM  based 
dosing,  but  subgroup  analyses  showed  that  Hispanic  and  African 
American patients could profit and those who’s HIV showed at least 
a partial response to one or more of the PIs which were part of ART 
[117]. Also another strategy of dose escalation could only improve 
therapy  response  in  patients  whose  virus  showed  at  least  a  partial 
susceptibility to a PI-based ART [118].
In  general,  a  meta-analysis  of  the  Cochrane  database  of  HIV-
TDM studies conducted between 2002 and 2007 (n=8) valuated the 
results critically. The methodological quality was considered good, but 
sample sizes being too small (n=40 to 230), too little information about 
randomization and also the heterogeneity of approaches, complicating 
a comparative meta-analysis. As a final result of this analysis it was 
stated by the authors that a general TDM should not be recommended 
in PI- or NNRTI-based ART, but the probability of virological response 
in patients taking an unboosted PI could be improved through TDM 
by 49% [119].
Also in one non-controlled trial a correlation between Ctrough of an 
NNRTI and virological response to ART was reported and a number 
of  further  retrospective  analyses  produced  prediction  models  for 
therapy success and/or the emergence of adverse events, thus regarding 
pharmacokinetics of ARVs in patients generally as relevant for therapy 
success [48,49,59,61,65,120-122]. Regarding protease inhibitors, one 
study investigated the pharmacokinetics of lopinavir/ritonavir dosed 
230/57.5 mg/m² body surface area (BSA) in children aged between 
birth and 12 years. In case lopinavir Ctrough were below 1 μg/mL the 
children  received  a  higher  dose  of  lopinavir  300/75  mg/m²  BSA 
[120]. Therapeutic outcome was similar in all children. A third study 
assessed pharmacokinetics in 13 pregnant women receiving 800/100 
mg saquinavir/ritonavir as HIV transmission prophylaxis during the 
third trimenon of pregnancy. If the women displayed a saquinavir 
AUC lower than 10.0 μg×h/mL their saquinavir dose was increased up 
to 1200 mg [78]. All women were successfully treated and none of the 
children was HIV-1 positive after birth.
Recently  a  French  working  group  presented  data  on  the  TDM 
of  efavirenz  and  a  successful  tailoring  of  efavirenz  doses  in  adult 
outpatients. The target concentrations of 1-4 μg/mL were reached in all 
patients after individualizing the efavirenz dose. Unfortunately these 
results did not indicate whether patients had less side effects after dose 
alteration, or whether this group of patients was compared to a standard 
dosing study arm (REF: HIV Pharmacology Amsterdam 2009).Citation: Hentig NV (2013) Personalizing HIV Therapy, Mission Impossible? J Antivir Antiretrovir 5: 012-020. doi:10.4172/jaa.1000058
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These examples show, that dose alterations were part of simple 
clinical  study  protocols  and  were  successfully  used  to  increase  the 
efficacy  of  plasma  concentration  governed  HAART.  Nevertheless, 
none  of  these  studies  used  population  pharmacokinetics,  PC-based 
simulations  of  dose  or  dosage  interval  changes  and  show  that  the 
integration of these still have not yet been introduced into clinical 
utility.
Discussion
It is current consensus that TDM can be useful in the evaluation 
of  non-compliance,  drug-related  toxicities,  provided  that  target 
concentrations are defined for this question, and in special patients 
groups, were the uncertainty about deriving sufficient or non-toxic 
plasma concentrations is due to a lack of experience and/or data, e.g. in 
children or pregnant women.
Nevertheless, personalizing HIV therapy on basis of the pk-derived 
prediction of exposure-response relationships, e.g. of the correlation 
between plasma concentrations, viral resistance and viral load decline, 
has not yet been used in practice for a pharmacological management 
of antiretroviral therapy. The currently best available approaches may 
be  the  use  of  genotypic  or  phenotypic  inhibitory  quotients  [36,38-
42,121,123-127],  which  is  nevertheless  methodologically  not  sound 
up to date. A predictivity of 80-97% for therapy response for different 
GIQ models is satisfying from a clinical point of view, but predictivity 
for therapy failure still ranges somewhat between 64 and 80%, showing 
a considerable lack of sensitivity, which in itself already makes the 
applicability of such models for their clinical use arguable.
Pharmacokinetic  modelling  of  HAART  correlated  to  patients´ 
demographics is already part of drug development and pharmacological 
science. Pk/pd models of HAART include the effects of drug potency, 
pharmacokinetics, adherence, drug resistance and viral dynamics on 
therapy outcome. However, the number of comprehensive models is 
scarce, their implications for clinical therapy remain restricted. 
In  addition  to  the  above  mentioned,  despite  all  efforts  for  the 
personalization  of  HAART,  there  are  problems  arising  from  the 
manufacturers  side.  There  is  a  trend  towards  oral  formulations  of 
ARVs which are dosed higher than previously in order to reduce the 
pill burden for patients and once-daily therapy regimens. Although 
this unquestionably contributes to patient´s compliance and quality 
of life, it deprives clinicians to tailor ARV doses individually due to 
the patient´s individual demands. The earlier change from saquinavir-
mesylate formulations of 200 mg per capsule to 500 mg per tablet, the 
increase of lopinavir/ritonavir dose from 133/33 mg per capsule to 
200/500 mg per film-coated tablet foils the efforts to personalize HIV 
therapy and the reduction of a dosage in order to reduce apparent 
toxicities bear a higher risk of losing therapeutic efficacy. Only lately 
lopinavir/ritonavir has been approved as 100/25 mg tablet formulation, 
which can be used now for individualizing doses to patients. Fixed dose 
combinations forge ahead on the market, Atripla® (efavirenz/tenofovir-
DF/emtricitabine) today has strong comparators such as Complera 
(rilpivirine/tenofovir-DF/emtricitabine)®  and  Stribild®  (elvitegravir/
cobicistat/tenofovir-DF/emtricitabine) and also the INI dolutegravir, 
which  probably  will  be  marketed  together  with  another  fixed  dose 
combination Kivexa® (lamivudine and abacavir) [128].
In general, dose alterations of standard NNRTI regimens should 
be applied very carefully, due to of the very low resistance barrier. 
Still,  body  weight  derived  dose  adaption  is  useful,  e.g.  in  case  of 
pediatric HIV therapy or patients with a very low or very high body 
weight. And it certainly is useful in order to estimate assumed drug-
drug interactions, e.g. with tuberculosis comedication, or metabolism 
disorders in case of e.g. actively replicating hepatitis B/C virus with 
signs of hepatic impairment.
Personalizing ART certainly is an issue in lifelong therapy, troubled 
with  side-effects  and  pill  burden,  given  to  millions  of  individuals 
worldwide  with  different  ethnic  backgrounds  and  characteristics. 
Ways to apply personalized therapy to clinical use have been shown by 
mathematicians, clinicians, biologists. However, the reality shows that 
prospective studies regarding this issue are still lacking, that the trend 
towards single tablet regimes and fixed dose combinations are foiling 
such efforts. Today, there are more antiretroviral drugs and classes on 
the marked than ever, more insight into mechanisms of viral inhibition 
and effect models, but ways to individualize therapy have become less.
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